Season 3

Season 3 Episode 1 – Not all PSMA agents are created equal

Season 3 Episode 2 – Stock market dynamics: not an exact science

Season 2

Season 2 Episode 1 – Banking on Copper

Season 2 Episode 2 – Pharma Wants a Wife

Season 2 Episode 3 – Building Better Therapies

Season 2 Episode 4 – A New Hope

Season 2 Episode 5 – Hot Copper – More precious than gold

Season 2 Episode 6 – If you are not in radiopharm, you are not serious

Season 2 Episode 7 – The Road Ahead

Season 1

The Science Hat Podcast – Full version

Episode 1. Who is Clarity and what drives our team forward?

Episode 2. Where do radiopharmaceuticals fit in the current cancer treatment landscape?

Episode 3. Targeted Copper Theranostics (TCTs) – The perfect pairing of Cu-64 for imaging and Cu-67 for treatment

Episode 4. What differentiates Clarity from other radiopharmaceutical companies?

Episode 5. SAR-bisPSMA – Optimised with two PSMA-targeting agents to better image and treat prostate cancer.

Episode 6.  SAR-Bombesin – Targeting a new protein in prostate cancer 

Episode 7. Challenges and opportunities in the emerging radiopharmaceutical market

Episode 8. Clarity maintains strong momentum as multiple clinical programs progress into Phase III trials.